Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) has been given a consensus rating of “Moderate Buy” by the fifteen research firms that are currently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, thirteen have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $137.0769.

A number of equities analysts recently weighed in on MIRM shares. TD Cowen upped their price target on Mirum Pharmaceuticals from $125.00 to $145.00 and gave the stock a “buy” rating in a report on Thursday, May 7th. Raymond James Financial reissued a “strong-buy” rating and set a $165.00 target price on shares of Mirum Pharmaceuticals in a report on Thursday, May 7th. Morgan Stanley increased their target price on Mirum Pharmaceuticals from $130.00 to $140.00 and gave the company an “overweight” rating in a report on Tuesday, May 5th. Weiss Ratings cut Mirum Pharmaceuticals from a “sell (d)” rating to a “sell (d-)” rating in a report on Friday, May 22nd. Finally, Wolfe Research initiated coverage on Mirum Pharmaceuticals in a report on Tuesday, May 19th. They set an “outperform” rating and a $145.00 target price for the company.

Insider Buying and Selling at Mirum Pharmaceuticals

In other Mirum Pharmaceuticals news, CEO Christopher Peetz sold 40,985 shares of the stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $91.98, for a total transaction of $3,769,800.30. Following the completion of the transaction, the chief executive officer owned 194,309 shares of the company’s stock, valued at $17,872,541.82. This represents a 17.42% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Joanne Quan sold 7,287 shares of the stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $91.98, for a total value of $670,258.26. Following the transaction, the insider directly owned 18,864 shares of the company’s stock, valued at $1,735,110.72. The trade was a 27.87% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 76,806 shares of company stock valued at $7,064,616. 14.36% of the stock is owned by insiders.

Institutional Investors Weigh In On Mirum Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Cullen Frost Bankers Inc. purchased a new position in Mirum Pharmaceuticals in the fourth quarter worth approximately $30,000. Eurizon Capital SGR S.p.A. purchased a new position in shares of Mirum Pharmaceuticals during the fourth quarter worth $32,000. CIBC Private Wealth Group LLC purchased a new position in shares of Mirum Pharmaceuticals during the fourth quarter worth $32,000. MCF Advisors LLC boosted its position in shares of Mirum Pharmaceuticals by 76.4% during the third quarter. MCF Advisors LLC now owns 427 shares of the company’s stock worth $31,000 after buying an additional 185 shares during the period. Finally, Quantbot Technologies LP acquired a new stake in shares of Mirum Pharmaceuticals in the third quarter valued at $33,000.

Mirum Pharmaceuticals Stock Performance

NASDAQ MIRM opened at $99.60 on Friday. The stock has a market capitalization of $6.07 billion, a price-to-earnings ratio of -7.32 and a beta of 0.52. Mirum Pharmaceuticals has a twelve month low of $43.30 and a twelve month high of $114.99. The company has a current ratio of 2.09, a quick ratio of 1.99 and a debt-to-equity ratio of 1.28. The stock has a 50-day moving average of $96.70 and a 200 day moving average of $89.36.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its quarterly earnings results on Wednesday, May 6th. The company reported ($13.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.75) by ($12.68). The business had revenue of $159.88 million during the quarter, compared to analyst estimates of $148.21 million. Mirum Pharmaceuticals had a negative return on equity of 11.28% and a negative net margin of 140.24%.The business’s revenue for the quarter was up 43.3% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.30) EPS. Sell-side analysts anticipate that Mirum Pharmaceuticals will post -2.11 EPS for the current fiscal year.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.